TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA2023 abstracts: What's hot in multiple myeloma and other plasma cell dyscrasias?

Jun 6, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.


To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

Top abstracts in multiple myeloma and other plasma cell dyscrasias

S100

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma

Hermann Einsele

S190

First results from the REDIRECTT-1 study with teclistamab (TEC) + talquetamab (TAL) simultaneously targeting BCAM and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Maria-Victoria Mateos 

S192

Talquetamab (TAL) + daratumumab (DARA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results

Nizar J Bahlis

S195

Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KARMMA-3 analysis in high-risk subgroups

Krina Patel

S197

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma

Hans C Lee

S199

A phase 3, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma (DREAMM-3)

Meletios Dimopoulos

S202

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

Nikhil Munshi

S203

Quadruplet induction therapy, ASCT and MRD-modulated consolidation and treatment cessation in newly diagnosed multiple myeloma: Final analysis of the MASTER trial

Luciano Costa

S204

Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain amyloidosis: 18-month results of a phase 2 study

Jason Valent

P870

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MAGNETISMM studies

Salomon Manier

Top abstracts by region

In addition to the top abstracts selected by our steering committee, the Multiple Myeloma Hub would like to highlight some key region-specific abstracts in the field of multiple myeloma and plasma cell dyscrasias.

Latin America

P954

Multiple myeloma in Latin America cancer registry: The MYLACRE study

Vania Hungria

P963

Extramedullary multiple myeloma: Clinical characteristics, impact, and outcomes in a cohort of patients in Mexico

Amaya Llorente Chávez

Asia Pacific

P952

Prognostic significance of dynamic change of MAGE-C1/CT7 in multiple myeloma: Ten year experience from a single center

Xuelin Dou

P976

Real-world outcomes of patients with penta-exposed multiple myeloma who were treated with selinexor and dexamethasone: Korean multicenter retrospective analysis

Jun Ho Yi

PB2146

Characteristics and outcomes of COVID-19 in patients with plasma cell disorders during the first omicron wave in Beijing since December 2022: A retrospective study at a tertiary center

Xuelin Dou

Middle East and Africa

PB2081

Cytogenetics of multiple myeloma in Morocco

Yasmine Moutmir

PB2160

Multiple myeloma in the elderly: A monocentric experience of the hematology department of Monastir (Tunisia)

Bizid Inaam

Europe

P944

Real-world patient characteristics and survival outcomes of lenalidomide refractory vs. lenalidomide exposed RRMM patients in the HONEUR federated data network

Ivan Spicka

P958

Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the UK, France, and Spain

Karthik Ramasamy

P981

Disease characteristics and treatment outcomes of myeloma patients <50 years of age: An analysis of the Balkan myeloma study group

Efstathios Kastritis

PB2137

Socio-demographic features and treatment patterns of multiple myeloma patients in Spain: an interim analysis of DORIANT study

Marta Grande

 

EHA 2023 top abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content